B-850040(B-850040) - _专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点-

作用方式-

作用机制-

治疗领域

肿瘤血液及淋巴系统疾病

在研适应症-

非在研适应症

白血病

原研机构

Siemens Healthcare Diagnostics GmbH

在研机构-

非在研机构

Siemens Healthcare Diagnostics GmbH

最高研发阶段终止临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C12H22N2O5Pt

InChIKeyFDEIZJZPVPINRB-UHFFFAOYSA-L

CAS号115597-07-4

关联

100 项与 B-850040 相关的临床结果

登录后查看更多信息

100 项与 B-850040 相关的转化医学

登录后查看更多信息

100 项与 B-850040 相关的专利（医药）

登录后查看更多信息

2

项与 B-850040 相关的文献（医药）

1990-01-01·Progress in clinical and biological research

Improved therapeutic index of cisplatin analogue: B-85-0040 by circadian timing.

Article

作者: Salzer, M ; von Roemeling, R ; Portuese, E ; Sothern, R ; Solis, O ; Bennett, J ; Sedlacek, H ; Hoffmann, D

1. B-85-0040 is a new cisplatin analogue with dose limiting myelosuppression. 2. The maximum tolerated dose ranges between 300 and 525 mg/kg for single i.p. bolus injection in mice. 3. Its toxicity is circadian-stage dependent with optimal tolerance between 16 and 17 hours after lights on. 4. B-85-0040 is active in L1210 leukemia. Anti-tumor activity seems to be unrelated to the circadian stage of treatment. Optimal drug timing can therefore increase its therapeutic index.

Progress in Clinical and Biological Research

Improved therapeutic index of cisplatin analog B-85-0040 by circadian timing

作者: Bennett, James ; Von Roemeling, Reinhard ; Portuese, Enrico ; Hoffmann, Dieter ; Solis, Otelo ; Sothern, Robert ; Sedlacek, H. Harald ; Salzer, Michael

B 85-0040 is a new cisplatin analog with dose-limiting myelosuppression.The maximum tolerated dose ranges between 300 and 525 mg/kg for single i.p. bolus injection in mice.Its toxicity is circadian-stage dependent with optimal tolerance between 16 and 17 h after lights on.B 85-0040 is active in L1210 leukemia.Antitumor activity seems to be unrelated to the circadian stage of treatment.Optimal drug timing can therefore increase its therapeutic index.

100 项与 B-850040 相关的药物交易

登录后查看更多信息